REFERENCES
- Ehtesham M, Black KL, Yu JS. Recent progress in immunotherapy for malignant glioma: Treatment strategies and results from clinical trials. Cancer Control 2004; 11: 192–207
- Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001; 61: 842–847
- Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004; 64: 4973–4979
- Rutkowski S, De Vleeschouwer S, Kaempgen E, et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br] Cancer 2004; 91: 1656–1662
- Yamanaka R, Homma J, Yajima N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: Results of a clinical phase I/II trial. Clin Cancer Res 2005; 11: 4160-4167
- Stupp R, Mason WP, van den Bent MI, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987–996
- Akasaki Y, Black KL, Yu JS. Dendritic cell-based immunotherapy for malignant gliomas. Expert Rev Neurother 2005; 5: 497–508
- Dunn GP, Ikeda H, Bruce AT, et al. Interferon-gamma and cancer immunoediting. Immunol Res 2005; 32: 231–246
- Gilboa E. The promise of cancer vaccines. Nat Rev Cancer 2004; 4: 401–411
- Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5: 296–306
- Matzinger P. The JAM test. A simple assay for DNA fragmentation and cell death. J Immunol Methods 1991; 145: 185–192
- Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432: 396–401